Renal Dysfunction in a Patient With Crohn's Disease During Ustekinumab Treatment: A Case Report and Review of the Literature

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current Therapeutic Research-clinical and Experimental Pub Date : 2024-01-01 DOI:10.1016/j.curtheres.2024.100753

Yuge Wei Ms , Gechong Ruan MD , Yan Qin MD , Xiaoyin Bai MD , Hong Yang MD

引用次数: 0

Abstract

Ustekinumab is a first-line drug for Crohn's disease. However, little is known about its potential adverse effects on renal function. We present the case of a 42-year-old man with Crohn's disease who developed chronic renal dysfunction during ustekinumab treatment, which resolved after discontinuing ustekinumab. The findings underscore the importance of close monitoring of renal function in patients receiving ustekinumab, particularly those with preexisting kidney disease or risk factors for renal dysfunction.

查看原文本刊更多论文

一名克罗恩病患者在接受乌司替库单抗治疗期间出现肾功能障碍：病例报告和文献综述

Ustekinumab 是治疗克罗恩病的一线药物。然而，人们对其对肾功能的潜在不良影响知之甚少。我们介绍了一例 42 岁的克罗恩病患者，他在接受乌司替库单抗治疗期间出现了慢性肾功能不全，在停用乌司替库单抗后症状缓解。这些发现强调了密切监测接受乌司替库单抗治疗的患者肾功能的重要性，尤其是已有肾脏疾病或存在肾功能障碍风险因素的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.